Stivarga and Abdominal fullness prematurely after meals - a phase IV clinical study of FDA data

Summary:

Abdominal fullness prematurely after meals is reported as a side effect among people who take Stivarga (regorafenib), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Fish Oil, and have Colon cancer.

The phase IV clinical study analyzes which people have Abdominal fullness prematurely after meals when taking Stivarga. It is created by eHealthMe based on reports of 9,530 people who have side effects when taking Stivarga from the FDA, and is updated regularly.

What is Stivarga?

Stivarga has active ingredients of regorafenib. eHealthMe is studying from 9,539 Stivarga users. Check the latest studies of Stivarga.

What is Abdominal fullness prematurely after meals?

Abdominal fullness prematurely after meals is found to be associated with 290 drugs and 919 conditions by eHealthMe. Check the latest studies of Abdominal fullness prematurely after meals.

On Jul, 20, 2026

9,530 people reported to have side effects when taking Stivarga.
Among them, 13 people (0.14%) have Abdominal fullness prematurely after meals.

Could Stivarga cause Abdominal fullness prematurely after meals?

Among these 13 people:

How long have people been on Stivarga when they have Abdominal fullness prematurely after meals? *

What is the gender of people who have Abdominal fullness prematurely after meals when taking Stivarga? *

female: 53.85 %
male: 46.15 %

What is the age of people who have Abdominal fullness prematurely after meals when taking Stivarga? *

What are other drugs people take besides Stivarga? *

What are other side effects people have besides Abdominal fullness prematurely after meals? *

Hoarseness Or Changing Voice: 11 people, 84.62%
Weight Decreased: 9 people, 69.23%
Nausea (feeling of having an urge to vomit): 8 people, 61.54%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 53.85%
Fatigue (feeling of tiredness): 7 people, 53.85%
Diarrhea: 6 people, 46.15%
Nausea And Vomiting: 6 people, 46.15%
Abdominal Pain Upper: 6 people, 46.15%
Back Pain: 6 people, 46.15%
Constipation: 5 people, 38.46%

What are the existing conditions these people have? *

Colon Cancer: 10 people, 76.92%
Joint Pain: 2 people, 15.38%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 2 people, 15.38%
Hepatocellular Carcinoma (liver cancer): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Stivarga and have Abdominal fullness prematurely after meals?

- Check whether Abdominal fullness prematurely after meals is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Stivarga:

Stivarga (9,539 reports)

Abdominal fullness prematurely after meals treatments and more:

Abdominal fullness prematurely after meals (2,183 reports)

How severe was Abdominal fullness prematurely after meals and when was it recovered:

Abdominal fullness prematurely after meals in Stivarga

Expand to all the drugs that have ingredients of regorafenib:

Abdominal fullness prematurely after meals and drugs with ingredients of regorafenib

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Stivarga:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Abdominal fullness prematurely after meals:

Abdominal fullness prematurely after meals (290 drugs)

Browse all the conditions that are associated with Abdominal fullness prematurely after meals:

Abdominal fullness prematurely after meals (919 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on regorafenib (the active ingredients of Stivarga) and Stivarga (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.